Released date: May 24, 2017

Competition for Patient Share in RA Treatment Heats Up

The partnership between Sanofi and Regeneron notched another victory with the regulatory approval of Kevzara® (sarilumab) for rheumatoid arthritis (RA). This comes after the approval of Dupixent® in March 2017 for severe atopic dermatitis. On May 23, 2017, FDA approved Kevzara®, the interleukin (IL-6) receptor blocker, for moderate to severe RA in patients with an inadequate response to disease-modifying anti-rheumatic drugs (DMARDs). This comes after the initial disappointment of receiving a Complete Response Letter from FDA in late 2016 due to deficiencies in the manufacturing process.